If you have Polyendocrine Metabolic Ovarian Syndrome (PMOS)—formerly known as PCOS—you've probably heard a familiar list of treatment options: birth control, metformin, spironolactone, lifestyle changes and fertility medications.

But another class of medications is getting increasing attention in PMOS care: GLP-1 medications.

You may know medications like semaglutide primarily for weight loss or diabetes. But when it comes to PMOS, their potential benefits can go deeper than the number on the scale.

That's because PMOS isn't simply an ovarian or reproductive condition. The recent change from Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome was specifically intended to better reflect the condition's complex hormonal and metabolic effects throughout the body.

And for some women, addressing that metabolic dysfunction may help improve several downstream symptoms at once.

First, what are GLP-1 medications?

GLP-1 is a hormone naturally produced in your gut after you eat. Among other functions, it helps regulate appetite, digestion, insulin release and blood sugar.

GLP-1 receptor agonists mimic some of these effects. Medications in this category include semaglutide and liraglutide.

They're most commonly associated with weight management and type 2 diabetes—but researchers have become increasingly interested in their potential role in PMOS.

In fact, international PMOS guidelines already state that GLP-1 medications such as semaglutide and liraglutide can be considered for the management of higher weight in adults with PMOS when appropriate.

So why might they be particularly useful for this condition?

1. They may help address insulin resistance

One of the most important pieces of PMOS is something you can't necessarily see: insulin resistance.

When your cells become less responsive to insulin, your body often compensates by producing more of it. Those higher insulin levels can then interact with the ovaries and contribute to increased androgen production.

This can create a frustrating cycle:

Insulin resistance → higher insulin → increased androgen production → worsening PMOS symptoms

GLP-1 medications can improve glucose regulation and, in some studies of women with PMOS, have improved measures of insulin resistance. A 2025 meta-analysis found GLP-1 receptor agonists significantly reduced body weight, BMI and insulin resistance compared with control treatments.

That matters because improving the metabolic environment may have effects beyond weight alone.

2. They may help lower androgen levels

Elevated androgens such as testosterone can contribute to some of the most frustrating symptoms of PMOS, including:

• acne
• increased facial or body hair
• scalp hair thinning
• irregular ovulation
• irregular menstrual cycles

Insulin can stimulate the ovaries to produce more androgens, so improving insulin resistance may help reduce that signal.

Research is still developing, but a 2024 meta-analysis found GLP-1 receptor agonist treatment was associated with reductions in total testosterone, along with improvements in body weight, waist circumference and triglycerides.

This doesn't mean GLP-1 medications should be considered an acne or hirsutism medication. But it highlights why treating the metabolic component of PMOS can sometimes influence symptoms that initially appear to be purely hormonal.

3. They may help regulate menstrual cycles and ovulation

This is where things get especially interesting.

When elevated insulin and androgens interfere with normal follicle development, ovulation can become irregular—or stop altogether.

As metabolic health improves, that hormonal environment may also become more favourable for regular ovulation.

Small studies of GLP-1 medications in PMOS have reported improvements in menstrual regularity and reproductive outcomes, and researchers are now actively studying whether these medications could have a larger role in PMOS-related fertility care.

However, the research isn't strong enough yet to consider GLP-1 medications fertility treatments themselves. A 2026 systematic review concluded that while GLP-1s produce modest short-term weight loss in women with PMOS and overweight or obesity, the evidence for reproductive and metabolic outcomes remains limited by the quality of existing studies.

In other words: promising, but we're still learning.

4. They can help interrupt the PMOS weight–insulin cycle

One of the most frustrating experiences for some women with PMOS is being told to simply "lose weight."

That advice can completely miss the metabolic reality of the condition.

Insulin resistance and other hormonal changes associated with PMOS can make appetite regulation and weight management more challenging. At the same time, increases in adipose tissue can further worsen insulin resistance.

It can become a self-reinforcing cycle.

For women who have PMOS alongside overweight or obesity, GLP-1 medications may provide another tool to interrupt that cycle by influencing appetite, satiety, glucose regulation and body weight.

And importantly, this isn't about blaming weight for PMOS.

Not everyone with PMOS lives in a larger body, and weight is not the sole cause of the condition. PMOS is a complex endocrine disorder with reproductive, metabolic and psychological features.

PMOS treatment shouldn't be one-size-fits-all

Perhaps the most exciting thing about GLP-1 research isn't that we've discovered a new "PMOS drug."

It's that we're finally beginning to treat PMOS like the whole-body endocrine and metabolic condition that it is.

For one woman, insulin resistance may be a major driver of her symptoms. For another, androgen excess, ovulatory dysfunction, thyroid abnormalities or other hormonal factors may play a greater role.

That's why treatment should start by understanding your individual hormonal and metabolic picture rather than simply treating individual symptoms in isolation.

At HorminaCare, we believe women deserve care that looks beyond a prescription for birth control or the advice to "eat less and exercise more." Through comprehensive assessment and lab testing, our practitioners work to identify the factors contributing to your symptoms and develop a treatment plan based on your individual results.

Think you may have PMOS or aren't getting the answers you need? Book a free consult with HorminaCare to learn more about your options.

This article is for educational purposes only and is not intended as individual medical advice. GLP-1 medications require assessment and prescribing by an appropriate healthcare provider.